Form 4: Boston Scientific Executive Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp, exercised stock options and sold 56,372 shares of common stock for over $102 per share under a Rule 10b5-1 trading plan.

Summary

• Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp (BSX), engaged in a pre-arranged transaction on June 4, 2025.
• He exercised options to acquire 56,372 shares of common stock at an exercise price of $26.15 per share.
• Concurrently, he sold all 56,372 shares of common stock at a weighted average sale price of $102.8814 per share, with prices ranging from $102.46 to $103.42.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Mr. Fitzgerald directly beneficially owns 178,342 shares of common stock and indirectly owns 5,234 shares through a child, for which he disclaims beneficial ownership.
• He also holds 250,000 unexercised stock options with an exercise price of $26.15, which vest in four equal annual installments starting December 1, 2018, and expire on December 1, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (exercise and sell) which is common for executive compensation and personal financial management. It does not indicate a positive or negative outlook on the company's future performance.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and transparent sale rather than an immediate reaction to market conditions.
• The executive realized a significant gain by exercising options at $26.15 and selling shares at an average of $102.8814, demonstrating the value of the company's stock performance.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors, though the context of option exercise and sale mitigates this.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction for an executive at Boston Scientific, a major player in the medical device industry, particularly in cardiology. Such transactions are common for executives managing their compensation and personal finances, and do not inherently reflect specific industry trends or competitive positioning.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 5,234 shares held by his child, which is disclosed as an indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if pre-planned, might be observed by shareholders, but the Rule 10b5-1 plan mitigates concerns about opportunistic selling. The executive's continued significant direct and derivative holdings suggest ongoing alignment with shareholder interests.

Key Dates

Keywords

Boston Scientific, BSX, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Executive Compensation, Joseph Michael Fitzgerald, Cardiology